HomeCompareMCRPF vs KMB

MCRPF vs KMB: Dividend Comparison 2026

MCRPF yields 127.39% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCRPF wins by $4.8K in total portfolio value
10 years
MCRPF
MCRPF
● Live price
127.39%
Share price
$1.57
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$50.7K
Annual income
$32.01
Full MCRPF calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — MCRPF vs KMB

📍 MCRPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMCRPFKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MCRPF + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MCRPF pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MCRPF
Annual income on $10K today (after 15% tax)
$10,828.03/yr
After 10yr DRIP, annual income (after tax)
$27.21/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, KMB beats the other by $4,402.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MCRPF + KMB for your $10,000?

MCRPF: 50%KMB: 50%
100% KMB50/50100% MCRPF
Portfolio after 10yr
$48.3K
Annual income
$2,621.67/yr
Blended yield
5.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

MCRPF
No analyst data
Altman Z
0.5
Piotroski
4/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MCRPF buys
0
KMB buys
0
No recent congressional trades found for MCRPF or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMCRPFKMB
Forward yield127.39%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%17%
Portfolio after 10y$50.7K$45.9K
Annual income after 10y$32.01$5,211.33
Total dividends collected$18.5K$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: MCRPF vs KMB ($10,000, DRIP)

YearMCRPF PortfolioMCRPF Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$17,069$6,369.43$11,314$613.68+$5.8KMCRPF
2$23,345$5,080.49$12,865$759.19+$10.5KMCRPF
3$28,226$3,246.85$14,709$943.96+$13.5KMCRPF
4$32,036$1,834.45$16,919$1,180.17+$15.1KMCRPF
5$35,251$972.93$19,588$1,484.33+$15.7KMCRPF
6$38,219$500.27$22,838$1,879.06+$15.4KMCRPF
7$41,148$253.46$26,832$2,395.60+$14.3KMCRPF
8$44,156$127.51$31,788$3,077.63+$12.4KMCRPF
9$47,311$63.94$38,000$3,986.82+$9.3KMCRPF
10$50,655$32.01$45,872$5,211.33+$4.8KMCRPF

MCRPF vs KMB: Complete Analysis 2026

MCRPFStock

MicroPort Scientific Corporation, an investment holding company, manufactures, and markets, and distributes medical devices in the People's Republic of China, North America, Europe, other Asian countries, South America, and internationally. The company's Cardiovascular Devices segment offers products and services for the treatment of coronary artery-related diseases; coronary stents and related delivery systems; and balloon catheters and accessories. Its Orthopedics Devices segment provides reconstructive joints, spine and trauma, and other professional implants and instruments. The company's Cardiac Rhythm Management Business segment offers defibrillators, cardiac resynchronization therapy devices, and pacemakers for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Its Endovascular and Peripheral Vascular Devices segment provides products and services for the interventional treatment of thoracic and abdominal aortic aneurysm, peripheral vascular diseases, aortic dissection, and other endovascular related diseases. The company's Neurovascular Devices segment offers neurovascular therapeutic and access devices for neurovascular diseases. Its Heart Valve Business segment provides VitaFlow Transcatheter aortic valve and delivery system, VitaFlow Liberty Transcatheter aortic valve implantation and retrievable delivery systems, Alwide Plus Balloon Catheter, various transcatheter aortic valve implantation, transcatheter mitral valve, transcatheter tricuspid valve, and surgical valve products. The company's Surgical Robot Business segment designs, develops, and commercializes surgical robots comprising robot ontology, control algorithm, electrical engineering, image-based navigation, and precision imaging. Its Surgical Devices segment researches and develops, manufactures, and sells surgical devices. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, the People's Republic of China.

Full MCRPF Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this MCRPF vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MCRPF vs SCHDMCRPF vs JEPIMCRPF vs OMCRPF vs KOMCRPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.